Analysts expected earnings of $2.56 per share on $50.35 billion in revenue, according to FactSet. UnitedHealth Group Inc (NYSE:UNH) has risen 32.76% since October 17, 2016 and is uptrending.
4 number of analysts have estimated the sales of the company for the quarter ending Oct 17, 2017, analysts estimated mean sale target of 53600.5 million while high and low sale targets are estimated at 54415.2 million and 52766.6 million respectively. During the same period previous year, the business posted $2.17 EPS. During the same period a year ago, the business posted $2.17 EPS.
After a recent look, shares have been seen 8.24% from the 200-day moving average, and -1.38% from the 50-day moving average. The company presently has a consensus rating of Buy and a consensus price target of $205.94. The firm has a market capitalization of $186.80 billion, a P/E ratio of 23.21 and a beta of 0.63. Shareholders of record on Friday, September 8th were given a dividend of $0.75 per share. The ex-dividend date was Thursday the 7th of September 2017. This represents a $3.00 annualized dividend and a dividend yield of 1.55%.
UnitedHealth Group (NYSE:UNH) had a decrease of 5.61% in short interest. New York-based Braun Stacey Assoc Incorporated has invested 1.13% in UnitedHealth Group Inc (NYSE:UNH). RBC Capital Markets maintained the shares of UNH in report on Wednesday, July 19 with "Buy" rating.
The consensus recommendation - averaging the work of 33 analysts - of 2.1 for Range Resources Corporation (RRC) points to moderate case. The stock of UnitedHealth Group Inc (NYSE:UNH) earned "Buy" rating by Piper Jaffray on Friday, August 25. Morgan Stanley raised their price objective on UnitedHealth Group from $202.00 to $210.00 and gave the company an overweight rating in a research note on Wednesday, June 28th. BALLARD WILLIAM C JR had sold 5,000 shares worth $913,211. The stock was sold at an average price of $193.98, for a total value of $969,900.00. Following the completion of the transaction, the director now owns 76,058 shares in the company, valued at approximately $14,753,730.84. The transaction was disclosed in a filing with the SEC, which is available at this link. The shares were sold at an average price of $198.11, for a total transaction of $10,019,215.14. It improved, as 53 investors sold UNH shares while 496 reduced holdings. Newbrook Capital Advisors Lp bought 154,932 shares as the company's stock rose 3.82% with the market.
Since May 4, 2017, it had 0 insider buys, and 3 insider sales for $10.13 million activity.
WPA2 protocol violated: Wi-Fi networks are vulnerable
The good news is that Vanhoef says that WPA2 can be patched to block the attack, and the patch will be backward compatible. A nonce is a number that is not necessarily a secret but is meant only to be used once and never repeated.
Several hedge funds and other institutional investors have recently made changes to their positions in UNH. UnitedHealth Group had 60 analyst reports since September 2, 2015 according to SRatingsIntel. The consensus rating is 2.3, suggesting the market has given up on the stock. Ltd. increased its position in shares of UnitedHealth Group by 433.3% during the second quarter. Copper Rock Capital Partners Llc owns 430,001 shares or 1.31% of their United States portfolio. Zweig stated it has 0.51% of its portfolio in UnitedHealth Group Inc (NYSE:UNH). Arrowstreet Capital Limited Partnership now owns 1,303,068 shares of the healthcare conglomerate's stock valued at $241,615,000 after purchasing an additional 300,744 shares in the last quarter. Finally, Alliancebernstein L.P. boosted its holdings in UnitedHealth Group by 2.3% in the second quarter.
Institutional ownership refers to the ownership stake in a company that is held by large financial organizations, pension funds or endowments.
ILLEGAL ACTIVITY WARNING: This article was first published by StockNewsTimes and is the sole property of of StockNewsTimes.
UnitedHealth Group Incorporated is a health and well-being company. The Firm operates through four divisions: UnitedHealthcare, OptumHealth, OptumInsight and OptumRx.
Revenue from its Optum business, which manages drug benefits and offers healthcare data analytics services, rose 8.4 percent to $22.89 billion, accounting for almost half of the insurer's total revenue.